drugset / Trial / NCT01471327

Japanese Phase 1 Study of Mepolizumab

NCT01471327

Phase 1 Completed 35 enrolled GlaxoSmithKline
RandomizedParallel-groupSingle-blindOther

Summary

SB-240563 is a fully humanized monoclonal antibody which is specific for human interleukin-5 (IL-5) and has been under development for severe refractory asthma. This study is the first study in Japanese subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single dose SB-240563 administered intravenously to Japanese healthy male subjects.

Timeline

Start
2011-08-09
Primary completion
2012-04-27
Completion
2012-04-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 10 mg Intravenous
Subject Mepolizumab Monoclonal antibody 75 mg Intravenous
Subject Mepolizumab Monoclonal antibody 250 mg Intravenous
Subject Mepolizumab Monoclonal antibody 750 mg Intravenous

Indications